BTK inhibitor (Boehringer Ingelheim/Albert Einstein Coll Med/Cleveland Clinic)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug NameBTK inhibitor (Boehringer Ingelheim/Albert Einstein Coll Med/Cleveland Clinic)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTyrosine-protein kinase BTK inhibitors
TargetsTyrosine-protein kinase BTK
Therapy Area/IndicationsLupus Nephritis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBoehringer Ingelheim Corp
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe Cleveland Clinic FoundationAlbert Einstein College Of Medicine IncBoehringer Ingelheim Corp
Active IndicationsN/A
Inactive IndicationsLupus Nephritis

Other Information

ATC CodeN/A
Related LinksN/A